<DOC>
	<DOCNO>NCT00994110</DOCNO>
	<brief_summary>The purpose study help u learn low patient 's risk common complication pancreas operation . After tumor remove remain part pancreas connect intestine close , leakage pancreatic fluid may occur . This fluid may form `` abscess '' ( collection pu ) `` fistula '' would need drain . A fistula persistent leakage pancreatic fluid sometimes occur pancreatic surgery . Fistulas , leak , abscess complication see roughly every 15-20 patient every 100 pancreas surgery . Complications like extend patient 's stay hospital surgery . These complication may require patient 's doctor perform additional test procedures treat . The physical emotional burden complication place upon patient , well financial cost health care system , great . The surgeon Memorial Sloan-Kettering Cancer Center conduct study determine drug , SOM230 , help reduce rate complication . SOM230 , also know Pasireotide , drug observe reduce rate similar complication study . The surgeon would like compare effect , good and/or bad , SOM230 `` placebo '' ( solution without medication ) see SOM230 reduces rate fistula , leaks abscess .</brief_summary>
	<brief_title>Placebo Controlled Trial SOM230 Reduction Post-Pancreatectomy Fistula , Leak , Abscess</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Fistula</mesh_term>
	<mesh_term>Pancrelipase</mesh_term>
	<criteria>Male female patient age 18 year great . Signed informed consent Candidate pancreaticoduodenectomy distal pancreatectomy without splenectomy . Pregnancy Patients malabsorption syndrome , short bowel chologenic diarrhea control specific therapeutic mean . Patients uncontrolled diabetes mellitus fast plasma glucose &gt; 250mg/dl . Note : At principle investigator 's discretion , noneligible patient rescreened adequate medical therapy institute . Patients congestive heart failure ( NYHA Class III IV ) , unstable angina , sustain ventricular tachycardia , ventricular fibrillation , clinically significant bradycardia , advanced heart block history acute myocardial infarction within six month precede enrollment . Patients risk QT prolongation . Risk factor include : patient electrolyte disturbance hypokalemia , hypomagnesemia , hypocalcemia ; patient family history long QT syndrome . syncope , idiopathic sudden death ; patient concomitant disease could prolong QT autonomic neuropathy ( cause diabetes , Parkinson 's disease ) , HIV , cirrhosis , uncontrolled hypothyroidism , bradycardia , highgrade AV block , significant cardiac arrhythmia , cardiac failure ; patient use concomitant medication know prolong QT interval receive protocol treatment . These medication include select antiarrhythmic , antihistamine , macrolide antibiotic , /or tricyclic antidepressant follow : Albuterol Alfuzosin Amantadine Amiodarone Amitriptyline Amphetamine Arsenic Trioxide Astemizole Atazanavir Atomoxetine Azithromycin Chloroquine Clomipramine Dolasetron Metaproterenol Moxifloxacin Phenermine Phenylpropanolamine Those drug specifically list possibly suspect cause QT prolongation would necessarily preclude patient registration , would discuss attend physician prior initiation protocol therapy . Patients QTc &gt; 450 msec . Patients liver disease cirrhosis , chronic active hepatitis chronic persistent hepatitis . Patients acute cholecystitis Patients presence active suspect acute chronic uncontrolled infection history immunocompromise , include positive HIV test result ( ELISA Western blot ) . Patients abnormal coagulation ( INR &gt; 1.5 ) patient receive anticoagulant affect PT ( prothrombin time ) APTT ( activate thromboplastin time ) Patients WBC &lt; 3 K/mcL ; PLT &lt; 100 K/mcL Patients current prior medical condition may interfere conduct study evaluation result opinion Investigator . Patients participate clinical investigation investigational drug ( pasireotide ) within 30 day prior dose . Known hypersensitivity somatostatin analogue component pasireotide octreotide LAR s.c. formulation Patients history noncompliance medical regimen consider potentially unreliable unable complete entire study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>PANCREAS</keyword>
	<keyword>Pasireotide</keyword>
	<keyword>SOM230</keyword>
	<keyword>saline placebo</keyword>
	<keyword>09-039</keyword>
</DOC>